Clinical trial · Observational
5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients
NCT06667583CI-TRIAL-00082148not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our study aims to detect 5p15/ 9q22/ 15q22 hyperdiploidy and thier significance in Multiple Myeloma patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma, Neoplasms | Multiple Myeloma | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- detection of 5p15/ 9q22/ 15q22 hyperdiploidy and thier significance in Multiple Myeloma patients
- timeFrame
- up to 2 yeqrs
- description
- detection of 5p15/ 9q22/ 15q22 hyperdiploidy and thier significance in Multiple Myeloma patients
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Newly diagnosed Multiple Myeloma Patients - Exclusion Criteria: Patient of Multiple Myeloma who received treatment \-
References
Publications (0)
Data not yet available
No reference posted for this study.